Verona Pharma VRNA 2021 Respiratory Disease Therapy Presentation

Verona Pharma presents ensifentrine, a Phase 3 first-in-class dual PDE3/PDE4 inhibitor for COPD maintenance treatment targeting a $10.5B market with significant unmet need. The company highlights efficacy demonstrated in two large Phase 2b trials, a favorable safety profile, and a targeted commercial opportunity focused on pulmonologist adoption and Medicare reimbursement.